Business Context and Reporting Period
This Form 8-K was filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on October 17, 2022. The report details a material definitive agreement entered into by Dominari Financial Inc., a wholly owned subsidiary of Aikido Pharma, with Kyle Wool. Mr. Wool is appointed as a consultant pending the termination of his current employment, after which he will assume the role of Chief Executive Officer of Dominari.
Key Financial Metrics and Compensation Structure
The filing does not report general corporate revenue, profit, cash flow, or debt metrics. It focuses exclusively on the compensation terms of the new executive agreement:
- Base Salary: $500,000 annually, paid in semi-monthly or bi-weekly installments.
- Performance Bonus (Cash + Stock): Tied to Dominari's annual revenue targets.
- $3.5M+ Revenue: $150,000 cash + 154,559 shares of Common Stock.
- $7.5M - $15M Revenue: $250,000 cash + 154,559 shares of Common Stock.
- $15M+ Revenue: $500,000 cash + 154,559 shares of Common Stock.
- Stock Valuation: The stock bonus component was valued at approximately $3,000,000 based on a closing price of $6.47 per share on October 14, 2022.
- Severance: In the event of termination without "Cause" or for "Good Reason," or within 40 days of a Change in Control, Mr. Wool is entitled to 12 months of base salary, COBRA health coverage, and pro-rated bonuses.
Material Changes and Conditions
The primary material change is the entry into the Amended and Restated Services Agreement. Key conditions include:
- Stockholder Approval: The issuance of stock bonuses is conditioned on stockholder approval of the 2022 Equity Incentive Plan by October 7, 2023.
- Forfeiture and Cash Conversion: If stockholder approval is not obtained by the deadline, the stock bonus is forfeited. Instead, Dominari must make a one-time cash payment equal to the value of the total potential shares (463,678 shares) multiplied by the closing stock price on the trading day preceding October 7, 2023.
- Role Transition: Mr. Wool's transition from consultant to CEO is contingent upon the termination of his current employment and FINRA registration.
Outlook, Risks, and Contingencies
Management Commentary: The agreement outlines a clear path for Mr. Wool to lead Dominari, with compensation heavily weighted toward achieving specific revenue milestones ($3.5M to $15M+).
Risks and Contingencies:
- Equity Plan Approval Risk: Failure to secure stockholder approval by October 7, 2023, triggers a significant cash liability for the company (potentially exceeding $3 million) rather than a stock issuance.
- Revenue Target Risk: The substantial portion of the bonus is contingent on Dominari achieving specific revenue thresholds for the first time in relevant calendar years.
- Termination Liability: The company faces a fixed liability of one year's salary plus pro-rated bonuses in specific termination scenarios.
Investor Verification Checklist
- Verify the status of the 2022 Equity Incentive Plan and whether stockholder approval has been or will be sought by October 7, 2023.
- Confirm the current employment status of Kyle Wool and his expected start date as CEO of Dominari.
- Review Dominari Financial Inc.'s current revenue trajectory to assess the attainability of the $3.5M, $7.5M, and $15M revenue targets.
- Check for any redacted portions in Exhibit 10.1 (the Services Agreement) that may contain additional restrictive covenants or definitions of "Cause" and "Good Reason."